Showing 3771-3780 of 4762 results for "".
- Brenton L. Saunders is Allergan's New Chairman of the Boardhttps://practicaldermatology.com/news/brenton-l-saunders-is-allergans-new-chairman-of-the-board/2458389/Brenton L. Saunders is Allergan’s new Chairman of the Board, the company reports. Effective today, Saunders will replace Paul Bisaro, who served as Executive Chairman since July 1, 2014. Bisaro will remain a member of the Allergan Board of
- The Election and The Marketshttps://practicaldermatology.com/news/the-election-and-the-markets/2458392/By David Mandell, JD, MBA and Robert Peelman, CFP® This presidential race is seemingly generating more interest, expressions of concern, and questions from clients than past elections. Some clients want to know how the election impacts our investment views and how we might ad
- Study Calls Attention to Negative Impact, Need for Treatment of SKhttps://practicaldermatology.com/news/study-calls-attention-to-negative-impact-need-for-treatment-of-sk/2458393/Patients with asymptomatic seborrheic keratosis (SK) are bothered by highly visible skin lesions and are very interested in treatment to improve their appearance, even if a cost were associated with treatment, according to a new study conducted in dermatology practices by Burke, Inc. on behalf of
- Oral Nalbuphine®ER Performs Well in Phase 2 Trial of Prurigo Nodularishttps://practicaldermatology.com/news/oral-nalbuphineer-performs-well-in-from-phase-2-trial-in-prurigo-nodularis/2458403/Trevi Therapeutics, Inc.’s Oral Nalbuphine®ER reduced itch intensity and improved quality of life in prurigo nodularis patients, according to a Phase 2 Trial. Nalbuphine ER is an oral extended release mu receptor an
- Encore Dermatology Introduces HylatopicPlus® Lotionhttps://practicaldermatology.com/news/encore-dermatology-introduces-hylatopicplus-lotion/2458402/Encore Dermatology, Inc. is expanding its line to with HylatopicPlus® Lotion in a 14 oz. bottle with pump dispenser. The Rx product relieves the burning, itching and pain experienced with various types of skin conditions, includi
- Vaseline Initiative Aims to Close Skin Heath Treatment Gaphttps://practicaldermatology.com/news/vaseline-initiative-aims-to-close-skin-heath-treatment-gap/2458405/The Vaseline® Healing Project in partnership with non-profit Direct Relief is working to close the skin health treatment gap for Americans by providing skin care and training along with Vaseline® products and medical supplies for those with limited access.<
- Eau Thermale Avène Launches #AveneHope for Eczema Awareness Monthhttps://practicaldermatology.com/news/eau-thermale-avne-launches-avenehope-for-eczema-awareness-month/2458411/Eau Thermale Avène is launching their #AveneHope program in recognition of Eczema Awareness Month this October. As part of the program, Avè
- ShoutStore Adds Medline Products to E-commerce Platformhttps://practicaldermatology.com/news/shoutstore-adds-medline-products-to-e-commerce-platform/2458413/ShoutStore entered into a new three-year partnership with Medline. Now, the global medical supplier's portfolio of disposable medical-surgical products, including exam gloves, bandages, gauze, gowns, and testing kits, will be available to ShoutStore's 7,500 online members across the count
- Valeant Appoints New Chief Quality Officerhttps://practicaldermatology.com/news/valeant-appoints-new-chief-quality-officer/2458416/Valeant Pharmaceuticals International, Inc. appointed Louis W. Yu, PhD to the newly created position of Chief Quality Officer, Global Quality, effective October 3, 2016. Dr. Yu reports to Joseph C. Papa, C
- Regeneron and Sanofi's Dupilumab Biologics License Application Accepted for Priority Review by FDAhttps://practicaldermatology.com/news/regeneron-and-sanofis-dupilumab-biologics-license-application-accepted-for-priority-review-by-fda/2458423/The FDA has accepted for priority review the Biologics License Application (BLA) for dupilumab from Regeneron Pharmaceuticals, Inc. and Sanofi for the treatment of adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD). The application has been given a Prescription